cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.60645/bdc-8afu-mq6j
title: Heart and Vascular Health Study (HVH)

description: 
**Objectives**<br/> The Heart and Vascular Health Study (HVH) is a case-control study of risk factors for the development of myocardial infarction (MI), stroke, venous thrombosis (VT), and atrial fibrillation (AF). The study setting is Group Health, an integrated health care delivery system in Washington State.

**Background**<br/> The HVH originated in 1988 with the examination of risk factors for MI. Over the ensuing years, the study has been funded by a series of grants, which have added case subjects with stroke, VT, and AF, and used a common control group. Study aims have focused on the associations of medication use with cardiovascular events. Starting in 1997, the study aims expanded to include genetic associations with cardiovascular disease. Participants recruited in 2009 or later and who provided blood samples for genetic analysis were asked for consent to deposit genetic and phenotype data in dbGaP.

**Design**<br/> As part of the HVH study, case subjects were identified by searching for ICD-9 codes consistent with MI, stroke, VT, or AF, and medical records were reviewed to confirm the diagnosis. Control subjects were identified at random from the Group Health enrollment and were matched to MI cases. All subjects have an index date. For cases, the index date was assigned as the date that the cardiovascular event (MI, stroke, VT, or AF) came to clinical attention. For controls, the index date was a random date within the range of the case index dates. For both cases and controls, information was collected from the inpatient and outpatient medical record, by telephone interview with consenting survivors, and from the Group Health pharmacy and laboratory databases. Consenting participants provided a blood specimen.

**Genetic Research**<br/> Genetic factors underlying cardiovascular disease are studied using DNA isolated from the blood samples.
DOI: 10.60645/bdc-0y02-9624
title: NHLBI TOPMed: Partners HealthCare Biobank

description: The Atrial Fibrillation Genetics Consortium (AFGen) was organized to identify common and rare genetic variation associated with atrial fibrillation risk. In the current study, we have performed whole genome sequencing in cases with early-onset atrial fibrillation. Samples in this study were enrolled as a part of the Partners HealthCare Biobank. Cases with early-onset atrial fibrillation were identified from the Biobank (defined as atrial fibrillation onset prior to 61 years and in the absence of structural heart disease).
DOI: 10.60645/bdc-ex8b-6drq
title: NHLBI TOPMed: Partners HealthCare Biobank

description: 
The Atrial Fibrillation Genetics Consortium (AFGen) was organized to identify common and rare genetic variation associated with atrial fibrillation risk. In the current study, we have performed whole genome sequencing in cases with early-onset atrial fibrillation. Samples in this study were enrolled as a part of the Partners HealthCare Biobank. Cases with early-onset atrial fibrillation were identified from the Biobank (defined as atrial fibrillation onset prior to 61 years and in the absence of structural heart disease).
DOI: 10.60645/bdc-8016-2s34
title: NHLBI TOPMed: The Vanderbilt Atrial Fibrillation Registry (VU_AF)

description: 
The Vanderbilt Atrial Fibrillation (AF) Registry was founded in 2001. Patients with AF and family members are prospectively enrolled. At enrollment a detailed past medical history is obtained along with an AF symptom severity assessment. Blood samples are obtained for DNA extraction. Patients are followed longitudinally along with serial collection of AF symptom severity assessments.
DOI: 10.60645/bdc-1mer-909o
title: NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women

description: The Women's Genome Health Study (WGHS) is a prospective cohort comprised of over 25,000 initially healthy female health professionals enrolled in the Women's Health Study, which began in 1992-1994. All participants in WGHS provided baseline blood samples and extensive survey data. Women who reported atrial fibrillation during the course of the study were asked to report diagnoses of AF at baseline, 48 months, and then annually thereafter. Participants enrolled in the continued observational follow-up who reported an incident AF event on at least one yearly questionnaire were sent an additional questionnaire to confirm the episode and to collect additional information. They were also asked for permission to review their medical records, particularly available ECGs, rhythm strips, 24-hour ECGs, and information on cardiac structure and function. For all deceased participants who reported AF during the trial and extended follow-up period, family members were contacted to obtain consent and additional relevant information. An end-point committee of physicians reviewed medical records for reported events according to predefined criteria. An incident AF event was confirmed if there was ECG evidence of AF or if a medical report clearly indicated a personal history of AF. The earliest date in the medical records when documentation was believed to have occurred was set as the date of onset of AF.
DOI: 10.60645/bdc-4q46-bg52
title: NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women

description: 
The Women's Genome Health Study (WGHS) is a prospective cohort comprised of over 25,000 initially healthy female health professionals enrolled in the Women's Health Study, which began in 1992-1994. All participants in WGHS provided baseline blood samples and extensive survey data. Women who reported atrial fibrillation during the course of the study were asked to report diagnoses of AF at baseline, 48 months, and then annually thereafter. Participants enrolled in the continued observational follow-up who reported an incident AF event on at least one yearly questionnaire were sent an additional questionnaire to confirm the episode and to collect additional information. They were also asked for permission to review their medical records, particularly available ECGs, rhythm strips, 24-hour ECGs, and information on cardiac structure and function. For all deceased participants who reported AF during the trial and extended follow-up period, family members were contacted to obtain consent and additional relevant information. An end-point committee of physicians reviewed medical records for reported events according to predefined criteria. An incident AF event was confirmed if there was ECG evidence of AF or if a medical report clearly indicated a personal history of AF. The earliest date in the medical records when documentation was believed to have occurred was set as the date of onset of AF.
DOI: 10.60645/bdc-sja0-0wts
title: MIGen_ExS: BioImage Study

description: 
The BioImage Study (BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population, [NCT00738725](https://clinicaltrials.gov/ct2/show/NCT00738725)), is a prospective, observational study aimed at characterizing subclinical atherosclerosis in U.S. adults (55 to 80 years old) at risk for clinical atherosclerotic cardiovascular disease (PMID: [25790876](http://www.ncbi.nlm.nih.gov/pubmed/25790876)).

All exome sequencing was performed at the Broad Institute of Harvard and MIT; samples sequence capture was performed using Illumina&#39;s ICE Capture reagent and sequencing was performed on an Illumina HiSeq 2000 or 2500.
DOI: 10.60645/bdc-owxv-0fnz
title: NHLBI TOPMed - NHGRI CCDG: Massachusetts General Hospital (MGH) Atrial Fibrillation Study

description: 
The Massachusetts General Hospital (MGH) Atrial Fibrillation Study was initiated in 2001. The study has enrolled serial probands, unaffected and affected family members with atrial fibrillation. At enrollment participants undergo a structured interview to systematically capture their past medical history, AF treatments, and family history. An electrocardiogram is performed; the results of an echocardiogram are obtained; and blood samples are obtained.

For the TOPMed WGS project only early-onset atrial fibrillation cases were sequenced. Early-onset atrial fibrillation was defined as an age of onset prior to 66 years of age.

Comprehensive phenotypic and pedigree data for study participants are available through dbGaP [phs001001](./study.cgi?study_id=phs001001).
DOI: 10.15468/dl.angetc
title: Occurrence Download

description: A dataset containing 204 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Prestoea ensiformis",
 "HasCoordinate is true",
 "BasisOfRecord is one of (Specimen)"
 ]
}

 The dataset includes 204 records from 15 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0016304-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.60645/bdc-7r32-c854
title: NHLBI TOPMed - NHGRI CCDG: Massachusetts General Hospital (MGH) Atrial Fibrillation Study

description: 
The Massachusetts General Hospital (MGH) Atrial Fibrillation Study was initiated in 2001. The study has enrolled serial probands, unaffected and affected family members with atrial fibrillation. At enrollment participants undergo a structured interview to systematically capture their past medical history, AF treatments, and family history. An electrocardiogram is performed; the results of an echocardiogram are obtained; and blood samples are obtained.

For the TOPMed WGS project only early-onset atrial fibrillation cases were sequenced. Early-onset atrial fibrillation was defined as an age of onset prior to 66 years of age.

Comprehensive phenotypic and pedigree data for study participants are available through dbGaP [phs001001](./study.cgi?study_id=phs001001).
DOI: 10.60645/bdc-d455-a765
title: Myocardial Infarction Genetics Exome Sequencing Consortium: Jackson Heart Study

description: 
 

This sub-study [phs001069](http://./study.cgi?study_id=phs001069) MIGen JHS contains sample phenotype and sequence data of subjects available from the [phs001069](http://./study.cgi?study_id=phs001069) study. Summary level phenotypes for the NHLBI JHS Cohort study participants can be viewed at the top-level study page [phs000286](./study.cgi?study_id=phs000286) JHS Cohort. Individual level data and sequence data for all JHS Cohort top-level study and substudies are available by requesting Authorized Access to the NHLBI JHS Cohort [phs000286](./study.cgi?study_id=phs000286) study.



The [Jackson Heart Study](http://www.jacksonheartstudy.org) (JHS) is a large, community-based, observational study whose participants were recruited from urban and rural areas of the three counties (Hinds, Madison and Rankin) that make up the Jackson, Mississippi, metropolitan statistical area (MSA). Participants were enrolled from each of the 4 recruitment pools: (1) random, 17%, (2) volunteer, 30%, (3) currently enrolled in the [Atherosclerosis Risk in Communities (ARIC) Study](https://www.nhlbi.nih.gov/science/atherosclerosis-risk-communities-aric-study), 31%, and (4) secondary family members, 22%. Recruitment was limited to non-institutionalized adult African Americans 35-84 years old, except in the family cohort where those 21 to 34 years of age were eligible. The final cohort of 5,301 participants includes 6.59% of all African American Jackson MSA residents aged 35-84 (N-76,426, US Census 2000). Major components of each exam include medical history, physical examination, blood/urine analytes and interview questions on areas such as: physical activity; stress, coping and spirituality; racism and discrimination; socioeconomic position; and access to health care. At 12-month intervals after the baseline clinic visit (Exam 1), participants are contacted by telephone to: update information; confirm vital statistics; document interim medical events, hospitalizations, and functional status; and obtain additional sociocultural information. Questions about medical events, symptoms of cardiovascular disease and functional status are repeated annually. Ongoing cohort surveillance includes abstraction of medical records and death certificates for relevant International Classification of Diseases (ICD) codes and adjudication of nonfatal events and deaths.

All exome sequencing was performed at the [Broad Institute of MIT and Harvard](https://www.broadinstitute.org/). Sample sequence capture was performed using Agilent SureSelect Human All Exon Kit v2 and sequencing was performed on an Illumina HiSeq 2000 or 2500.
DOI: 10.60645/bdc-u98e-4l3i
title: Myocardial Infarction Genetics Exome Sequencing Consortium: Jackson Heart Study

description: 
 

This sub-study [phs001069](http://./study.cgi?study_id=phs001069) MIGen JHS contains sample phenotype and sequence data of subjects available from the [phs001069](http://./study.cgi?study_id=phs001069) study. Summary level phenotypes for the NHLBI JHS Cohort study participants can be viewed at the top-level study page [phs000286](./study.cgi?study_id=phs000286) JHS Cohort. Individual level data and sequence data for all JHS Cohort top-level study and substudies are available by requesting Authorized Access to the NHLBI JHS Cohort [phs000286](./study.cgi?study_id=phs000286) study.



The [Jackson Heart Study](http://www.jacksonheartstudy.org) (JHS) is a large, community-based, observational study whose participants were recruited from urban and rural areas of the three counties (Hinds, Madison and Rankin) that make up the Jackson, Mississippi, metropolitan statistical area (MSA). Participants were enrolled from each of the 4 recruitment pools: (1) random, 17%, (2) volunteer, 30%, (3) currently enrolled in the [Atherosclerosis Risk in Communities (ARIC) Study](https://www.nhlbi.nih.gov/science/atherosclerosis-risk-communities-aric-study), 31%, and (4) secondary family members, 22%. Recruitment was limited to non-institutionalized adult African Americans 35-84 years old, except in the family cohort where those 21 to 34 years of age were eligible. The final cohort of 5,301 participants includes 6.59% of all African American Jackson MSA residents aged 35-84 (N-76,426, US Census 2000). Major components of each exam include medical history, physical examination, blood/urine analytes and interview questions on areas such as: physical activity; stress, coping and spirituality; racism and discrimination; socioeconomic position; and access to health care. At 12-month intervals after the baseline clinic visit (Exam 1), participants are contacted by telephone to: update information; confirm vital statistics; document interim medical events, hospitalizations, and functional status; and obtain additional sociocultural information. Questions about medical events, symptoms of cardiovascular disease and functional status are repeated annually. Ongoing cohort surveillance includes abstraction of medical records and death certificates for relevant International Classification of Diseases (ICD) codes and adjudication of nonfatal events and deaths.

All exome sequencing was performed at the [Broad Institute of MIT and Harvard](https://www.broadinstitute.org/). Sample sequence capture was performed using Agilent SureSelect Human All Exon Kit v2 and sequencing was performed on an Illumina HiSeq 2000 or 2500.
DOI: 10.60645/bdc-4fr1-9670
title: Myocardial Infarction Genetics Exome Sequencing Consortium: Jackson Heart Study

description: 
 

This sub-study [phs001069](http://./study.cgi?study_id=phs001069) MIGen JHS contains sample phenotype and sequence data of subjects available from the [phs001069](http://./study.cgi?study_id=phs001069) study. Summary level phenotypes for the NHLBI JHS Cohort study participants can be viewed at the top-level study page [phs000286](./study.cgi?study_id=phs000286) JHS Cohort. Individual level data and sequence data for all JHS Cohort top-level study and substudies are available by requesting Authorized Access to the NHLBI JHS Cohort [phs000286](./study.cgi?study_id=phs000286) study.



The [Jackson Heart Study](http://www.jacksonheartstudy.org) (JHS) is a large, community-based, observational study whose participants were recruited from urban and rural areas of the three counties (Hinds, Madison and Rankin) that make up the Jackson, Mississippi, metropolitan statistical area (MSA). Participants were enrolled from each of the 4 recruitment pools: (1) random, 17%, (2) volunteer, 30%, (3) currently enrolled in the [Atherosclerosis Risk in Communities (ARIC) Study](https://www.nhlbi.nih.gov/science/atherosclerosis-risk-communities-aric-study), 31%, and (4) secondary family members, 22%. Recruitment was limited to non-institutionalized adult African Americans 35-84 years old, except in the family cohort where those 21 to 34 years of age were eligible. The final cohort of 5,301 participants includes 6.59% of all African American Jackson MSA residents aged 35-84 (N-76,426, US Census 2000). Major components of each exam include medical history, physical examination, blood/urine analytes and interview questions on areas such as: physical activity; stress, coping and spirituality; racism and discrimination; socioeconomic position; and access to health care. At 12-month intervals after the baseline clinic visit (Exam 1), participants are contacted by telephone to: update information; confirm vital statistics; document interim medical events, hospitalizations, and functional status; and obtain additional sociocultural information. Questions about medical events, symptoms of cardiovascular disease and functional status are repeated annually. Ongoing cohort surveillance includes abstraction of medical records and death certificates for relevant International Classification of Diseases (ICD) codes and adjudication of nonfatal events and deaths.

All exome sequencing was performed at the [Broad Institute of MIT and Harvard](https://www.broadinstitute.org/). Sample sequence capture was performed using Agilent SureSelect Human All Exon Kit v2 and sequencing was performed on an Illumina HiSeq 2000 or 2500.
DOI: 10.60645/bdc-twk0-d469
title: Myocardial Infarction Genetics Exome Sequencing Consortium: Jackson Heart Study

description: 
 

This sub-study [phs001069](http://./study.cgi?study_id=phs001069) MIGen JHS contains sample phenotype and sequence data of subjects available from the [phs001069](http://./study.cgi?study_id=phs001069) study. Summary level phenotypes for the NHLBI JHS Cohort study participants can be viewed at the top-level study page [phs000286](./study.cgi?study_id=phs000286) JHS Cohort. Individual level data and sequence data for all JHS Cohort top-level study and substudies are available by requesting Authorized Access to the NHLBI JHS Cohort [phs000286](./study.cgi?study_id=phs000286) study.



The [Jackson Heart Study](http://www.jacksonheartstudy.org) (JHS) is a large, community-based, observational study whose participants were recruited from urban and rural areas of the three counties (Hinds, Madison and Rankin) that make up the Jackson, Mississippi, metropolitan statistical area (MSA). Participants were enrolled from each of the 4 recruitment pools: (1) random, 17%, (2) volunteer, 30%, (3) currently enrolled in the [Atherosclerosis Risk in Communities (ARIC) Study](https://www.nhlbi.nih.gov/science/atherosclerosis-risk-communities-aric-study), 31%, and (4) secondary family members, 22%. Recruitment was limited to non-institutionalized adult African Americans 35-84 years old, except in the family cohort where those 21 to 34 years of age were eligible. The final cohort of 5,301 participants includes 6.59% of all African American Jackson MSA residents aged 35-84 (N-76,426, US Census 2000). Major components of each exam include medical history, physical examination, blood/urine analytes and interview questions on areas such as: physical activity; stress, coping and spirituality; racism and discrimination; socioeconomic position; and access to health care. At 12-month intervals after the baseline clinic visit (Exam 1), participants are contacted by telephone to: update information; confirm vital statistics; document interim medical events, hospitalizations, and functional status; and obtain additional sociocultural information. Questions about medical events, symptoms of cardiovascular disease and functional status are repeated annually. Ongoing cohort surveillance includes abstraction of medical records and death certificates for relevant International Classification of Diseases (ICD) codes and adjudication of nonfatal events and deaths.

All exome sequencing was performed at the [Broad Institute of MIT and Harvard](https://www.broadinstitute.org/). Sample sequence capture was performed using Agilent SureSelect Human All Exon Kit v2 and sequencing was performed on an Illumina HiSeq 2000 or 2500.
DOI: 10.60645/bdc-i9nj-8319
title: GeneSTAR NextGen Functional Genomics of Platelet Aggregation

description: 
The causal mechanisms of common diseases and their therapies have been only marginally illuminated by genetic variants identified in genome wide association studies (GWAS) utilizing single nucleotide polymorphism (SNPs). Platelet activation pathways reflecting hemostasis and thrombosis are the underlying substrate for many cardiovascular diseases and related acute events. To overcome GWAS limitations, genomic studies are needed that integrate molecular surrogates for platelet-related phenotypes assayed in cell-based models derived from individuals of known genotypes and phenotypes. In our GWAS study of native platelet aggregation phenotypes and aggregation in response to low dose aspirin in 2200 subjects (GeneSTAR, Genetic Study of Aspirin Responsiveness), important genome wide "signals" (p&lt;5x10-8) associated with native platelet aggregation and important "signals" associated with platelet responsiveness to aspirin were identified and replicated. Although we are currently performing functional genomics studies to elucidate our most promising findings in known genes (PEAR1, MET, PIKC3G), most "signals" occurred in intergenic regions or in introns. Mechanistic interpretation is limited by uncertainty as to which gene(s) are up- or down-regulated in the presence of most SNP modifications. In this 3 phase proposal, we will (1) create pluripotent stem cells (iPS) from peripheral blood mononuclear cells, and then differentiate these stem cells into megakaryocytes (2) develop an efficient strategy to produce iPS and megakaryocytes using a novel pooling method, and (3) produce iPS and megakaryocytes from 250 subjects in GeneSTAR (European Americans and African Americans), selected based on specific hypotheses derived from GWAS signals in native and post aspirin platelet function; characterize genetic mRNA transcripts using a comprehensive Affymetrix array; measure protein expression for transcripts of interest using mass spectrometry; examine mRNA and protein expression patterns for each GWAS signal to determine the functional pathway(s) involved in native platelet phenotypes; and examine the functional genomics of variations in responsiveness to aspirin using our prior genotyped and phenotyped population. Precise information about the exact functional processes in megakaryocytes and platelets may lead to innovative and tailored approaches to risk assessment and novel therapeutic targets to prevent first and recurrent cardiovascular and related thrombotic events.
DOI: 10.15468/dl.g63cfz
title: Occurrence Download

description: A dataset listing the 9 species recorded in GBIF matching the query:
{
 "DatasetKey" : [
 "is Inventaires Aéro Biodiversité - LFGI - Dijon Darois-Inventaires Aéro Biodiversité - LFGI - Point d'EPOC 2"
 ]
}

 The dataset's 9 records were derived from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0016297-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.